Group 1 - Zhaoyi Innovation (03986) saw an intraday increase of 1.72% amid rising shipping risks in the Hormuz Strait affecting the supply chain of key raw materials like helium [1] - Rongchang Bio (09995) rose over 3.6% after its RC288 injection application was accepted by NMPA, showing excellent anti-tumor activity and safety in preclinical studies [1] - Swire Properties (01972) increased by over 2.2% following the release of its 2025 full-year results, reporting revenue of HKD 16.041 billion, a year-on-year increase of 11%, and a basic earnings per share of HKD 1.49 [1] Group 2 - Health 160 (02656) surged over 10%, reaching a new high of HKD 140.5, with a nearly doubled stock price since March 9, despite a previous drop of about 30% on February 11 [2] - Gaming stocks collectively rose, with notable increases in companies like Boyaa Interactive (00434) up 4.44% and Tencent (00700) up 1.1%, following Apple's announcement of a commission rate adjustment for the App Store in mainland China [2] - Qidian Guofeng (01280) experienced a significant rise of over 26% after announcing a sales contract for AI servers with an independent third party [2] Group 3 - Hong Kong bank stocks fell again, with Standard Chartered (02888) down 4.67% and HSBC Holdings (00005) down 3.8%, amid ongoing tensions in the Middle East affecting transactions involving Asian balance sheets [3] - Cement stocks saw a general increase, with China National Building Material (03323) up 2.62%, as construction activity picked up post-Lantern Festival, leading to a steady recovery in cement market demand [3] - Domestic property stocks rebounded, with CIFI Holdings (00884) up 2.9% and Sunac China (01918) up 5.45%, as recent data indicated a 3.3% year-on-year decline in second-hand housing listings in Shenzhen [4] Group 4 - Yao Cai Securities (01428) saw a significant rise of over 39% after extending the acquisition offer deadline with Ant Group to March 25, 2026 [4] - PayPay (PAYP.US), a digital wallet operator backed by SoftBank, debuted on the US stock market with a 13.5% increase, achieving a market cap of nearly USD 12 billion [5] - Chinese electric vehicle companies NIO (NIO.US) and Xpeng Motors (XPEV.US) saw stock increases of 1.46% and 3.58%, respectively, amid discussions of potential collaborations with European automotive giant Stellantis [5] Group 5 - Storage stocks collectively declined, with SanDisk (SNDK.US) down 5.59% and Micron Technology (MU.US) down 3.19%, following negative sentiment from short-seller Citron Capital [6] - Optical communication stocks fell, with Applied Optoelectronics (AAOI.US) down 16.39%, despite securing a bulk order for a new data center transceiver [6] - Agricultural input stocks continued to rise, with CF Industries Holdings (CF.US) up 13.21%, driven by supply chain disruptions in the Middle East affecting fertilizer transportation [7] Group 6 - Oil stocks rose sharply, with Battalion Oil (BATL.US) up 15.48% as international oil prices surged, with WTI crude rising over 8% to USD 94.66 [8] - EHang Intelligent (EH.US) reported total revenue of RMB 509.5 million (approximately USD 72.9 million) for the fiscal year 2025, marking an 11.7% year-on-year increase, despite a net loss of RMB 231 million [8]

Core Insights - The value of goods imported from China to Cameroon increased by 25% year-on-year in the second quarter of 2025, reaching 226.8 billion CFA francs (approximately $3.9 million) [1] - The total import volume during the period was 492,013 tons, compared to 438,218 tons in the same period of 2024 [1] Group 1: Key Drivers of Import Growth - The primary driver of this growth was the import of automobiles and parts, which nearly doubled in value from 13.3 billion CFA francs in the second quarter of 2024 to 26.2 billion CFA francs in 2025 [2] - Steel product imports also accelerated significantly, with the value reaching 44.9 billion CFA francs in the second quarter of 2025, up from 11.1 billion CFA francs in the same period of 2024 [2] - Agricultural inputs, particularly pesticides, fungicides, and herbicides, saw a slight increase in import value, estimated at 17.01 billion CFA francs compared to 15.9 billion CFA francs a year earlier [2] Group 2: Import Source Structure - During the review period, 69% of the total value of goods unloaded at the ports of Douala and Kribi came from 11 countries, with China leading at 20% of total imports [3] - Following China, Togo accounted for 15%, while India, Belgium, and France each contributed 7% [3] - This source structure highlights the importance of Asian and regional trade partners in Cameroon’s supply chain, confirming China's dominant position in Cameroon’s foreign trade [3]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenues of $74.7 million, a 40% decline year-over-year, primarily due to a winding down of the seed business and reduced demand for crop inputs in Argentina [6][7][8] - For the full fiscal year, revenues totaled $335.3 million, down 28% year-over-year, with declines across all segments [8][12] - Adjusted EBITDA for Q4 was -$4.5 million, down from $19.9 million the previous year, largely due to a $22.7 million reduction in gross profit [13][15] - Full-year EBITDA was $28.3 million, down from $81.4 million in FY24, reflecting a $54.6 million decline in gross profit [15][18] Business Line Data and Key Metrics Changes - In the seed segment, revenues were $63.9 million for the year, a reduction of 34%, attributed to the transition to a royalty-based model [9][12] - Crop protection revenues for the full year were $181.9 million, down 20%, with a strong decline in Argentina offset by growth in bioprotection in the U.S. and adjuvants in Brazil [8][12] - Crop nutrition revenues were $89.5 million, down 37% year-over-year, driven by lower microbiota fertilizer sales in Argentina [8][12] Market Data and Key Metrics Changes - The company experienced a significant decline in sales in Argentina due to adverse on-farm economics and reduced spending on agricultural inputs [5][6] - International sales of core technologies grew, with adjuvant sales in Brazil almost doubling and bioprotection products in the U.S. growing nearly 40% [7][8] Company Strategy and Development Direction - The company is focusing on cash generation and improving working capital management, targeting a running rate of 5 to 6 months of sales [19][20] - Cost structure adjustments are being accelerated, with targeted operating expense savings of around 10% to 12% [19][20] - The company aims to scale up biological initiatives and support key partners in Latin America while onboarding new partnerships in the U.S. and Australia [21][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in fiscal 2025, attributing them to a combination of macroeconomic shifts in Argentina and changes in the HB4 seed business strategy [4][5] - The company expects to improve EBITDA margins and progress towards a more robust balance sheet with a normalized agricultural input market in Argentina and continued growth in the U.S. and Brazil [20][22] Other Important Information - Total financial debt stood at $255.5 million, slightly lower than the previous quarter, reflecting repayments of unsecured public bonds and working capital loans [17][18] - Cash and cash equivalents totaled $34.6 million, resulting in a net financial debt of $220.8 million as of June 30, 2025 [18] Q&A Session Summary Question: What metrics should be focused on in the next six to nine months? - Management emphasized cash generation and profitability expansion as key metrics, with less priority on top-line growth under current circumstances [24][25] Question: Can you elaborate on cost savings initiatives? - Management indicated that cost savings of $3 to $3.5 million per quarter are expected, achieved through workforce streamlining and right-sizing capacities [29][31] Question: What was the gross profit from the Syngenta agreement in fiscal 2025? - Management clarified that the gross profit from Syngenta for the fiscal year was approximately $18 million, with no upfront payment recognized this year [34][36] Question: What is the outlook for the HB4 product? - Management highlighted a significant agreement with GDM to reposition HB4 technology for weed control, which is expected to generate revenues in the upcoming fiscal year [42][43] Question: How is the inventory situation in Argentina? - Management noted that inventory levels have been almost depleted, indicating a potential recovery in sales as planting needs arise [60][61]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenues of $74.7 million, a 40% decline year-over-year, primarily due to the winding down of the seed business and reduced demand for crop inputs in Argentina [6][8][9] - For the full fiscal year, revenues totaled $335.3 million, down 28% year-over-year, with declines across all segments [8][12] - Adjusted EBITDA for Q4 was -$4.5 million, down from $19.9 million the previous year, largely due to a $22.7 million reduction in gross profit [13][15] - Full-year EBITDA was $28.3 million, down from $81.4 million in FY24, reflecting a $54.6 million decline in gross profit [15][18] Business Line Data and Key Metrics Changes - In the seed segment, revenues were $63.9 million for the year, a reduction of 34%, attributed to the transition to a royalty-based model [9][12] - Crop protection revenues for the full year were $181.9 million, down 20%, with a strong decline in Argentina offsetting growth in bioprotection in the U.S. and adjuvants in Brazil [8][12] - Crop nutrition revenues were $89.5 million, down 37% year-over-year, driven by lower microbiota fertilizer sales in Argentina [8][12] Market Data and Key Metrics Changes - International sales of core technologies grew, with adjuvant sales in Brazil almost doubling and bioprotection products in the U.S. growing nearly 40% [7] - The company experienced a significant decline in sales in Argentina due to adverse on-farm economics and reduced spending on agricultural inputs [5][6] Company Strategy and Development Direction - The company is focusing on cash generation and improving working capital management, targeting a running rate of five to six months of sales [19][20] - Cost structure adjustments are being accelerated, with targeted operating expense savings of around 10%-12% [19][20] - The company aims to scale up biological initiatives and support key partners in Latin America while onboarding new partnerships in the U.S. and Australia [21][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in fiscal 2025, primarily due to macroeconomic shifts in Argentina and a lack of inventory incentives for clients [4][5] - The company expects to improve EBITDA margins and progress towards a more robust balance sheet with a normalized agricultural input market in Argentina and continued growth in the U.S. and Brazil [20][21] - Management emphasized the importance of cash generation and profitability expansion over top-line growth in the current environment [25][26] Other Important Information - Total financial debt stood at $255.5 million, slightly lower than the previous year, with cash and equivalents totaling $34.6 million [17][18] - The company is working closely with creditors to comply with financial obligations and manage upcoming debt maturities [20] Q&A Session Summary Question: What metrics should be focused on in the next six to nine months? - Management indicated that cash generation and profitability expansion will be key metrics, with less emphasis on top-line growth under current circumstances [25][26] Question: Can you elaborate on cost savings initiatives? - Management expects to achieve quarterly savings of $3 million-$3.5 million through workforce streamlining and right-sizing capacities [29][31] Question: What was the gross profit from the Syngenta agreement in FY2025? - The gross profit from the Syngenta agreement for FY2025 was approximately $18 million, down from $16 million in the previous year [35][37] Question: What efforts have been made regarding the HB4 product? - Management highlighted a key agreement in soybeans to reposition HB4 technology, which is expected to generate revenues in the upcoming fiscal year [43][44] Question: What is the current state of inventories in the channel? - Management noted that inventory levels in Argentina have been almost depleted, indicating a potential recovery in sales [62][63]

Financial Data and Key Metrics Changes - Total revenues for the quarter were $60.6 million, down from $84 million in the same period last year, primarily due to the absence of a significant accrual from Syngenta's initial down payment [9][10] - Gross profit decreased to $24 million from $42.6 million year-over-year, with gross margin declining from 51% to 39% due to the previous year's accrual effect [14][15] - Adjusted EBITDA for the quarter was $9 million, down from $21.1 million last year, reflecting the impact of the Syngenta down payment accrual [17][18] - Cash from operating activities improved significantly to $23.3 million, a $40.7 million increase compared to the prior year's cash requirement of $17 million [20][21] - Total debt decreased by $13 million, leading to a leverage ratio of 4.1 at the end of the quarter [23] Business Line Data and Key Metrics Changes - Crop Protection revenues decreased due to lower sales of non-core products in Argentina, partially offset by higher sales of bioprotection solutions [14] - Integrated Products revenues increased by 26%, driven by accelerated sales of HB4 grain from existing inventory [14] - Inoculant sales showed underlying operational growth, slightly offset by seasonal effects on fertilizers [14] Market Data and Key Metrics Changes - The Argentine market experienced reduced commercial activity, with purchasing behavior becoming more aligned with the agronomic calendar rather than speculative patterns [10][11] - The U.S. and Mexico markets showed good growth, indicating early signs of recovery, while Brazil remained in a low season with positive sentiment due to improved soybean prices [12][13] - Overall, the performance in Argentina was not indicative of market status, with expectations for better conditions in the upcoming summer crop season [12][13] Company Strategy and Development Direction - The company is transitioning to a more sustainable agricultural model, focusing on cash flow performance and working capital efficiency [6][20] - The long-awaited EPA approval of Rhinotech allows the company to offer a full suite of biological solutions for pest control and plant health [6] - The company aims to reduce reliance on the Argentine market, targeting growth in Brazil, the U.S., and Europe [70] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the Argentine market, noting improved macroeconomic conditions and stable farmer sentiment [51][52] - The company anticipates a healthy winter crop season in Argentina, with expectations for a stronger summer crop season [52][53] - Management highlighted the importance of maintaining operational excellence and leveraging technology platforms for future growth [60][70] Other Important Information - The company has implemented a significant reduction in payroll and structural costs, resulting in annualized savings of approximately $5 million [28] - The Rhinotech platform is positioned for a prelaunch year in 2025, with registrations ongoing in key markets [30][31] Q&A Session Summary Question: Inquiry about cash advancement and working capital unwind - Management indicated an expected additional $10 million from the transition to a lighter model with HB4, aiming for a return to historical net working capital levels of four to four and a half months of sales [44][45] Question: Sentiment in Argentina and macroeconomic conditions - Management noted that sentiment in Argentina is slowly building up, with stable macroeconomic conditions leading to normalized purchasing behavior [50][51] Question: Non-operating income payment details - The $7.5 million non-operating income payment was primarily non-cash, involving an exchange of IP and intangible assets [65] Question: Field trial results for Neovil product - Management confirmed ongoing replicated third-party field trials for Neovil, with positive feedback from strategic and channel partners [94] Question: Interest in HB4 traits from seed companies - Management confirmed ongoing collaboration with public and private institutions for HB4 wheat in the U.S., with a focus on Latin America for HB4 soybeans [97][98]